Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 1,4-Butanediol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Butanediol SCHEMBL167828 | 1.00 | CA5A (0.57) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 | |
| 1,4-Butanediol SCHEMBL9322154 | 1.00 | CA5A (0.57) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 | |
| Nitric Acid SCHEMBL25202723 | 0.97 | CA5A (0.53) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 | |
| Nitric Acid SCHEMBL25180668 | 0.97 | CA5A (0.53) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 | |
| 1,5-Pentanediol SCHEMBL9875084 | 0.97 | CA5A (0.53) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 | |
| Nitric Acid SCHEMBL25264224 | 0.97 | CA5A (0.53) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 | |
| Nitric Acid SCHEMBL25180692 | 0.97 | CA5A (0.53) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 | |
| Nitric Acid SCHEMBL9874805 | 0.97 | CA5A (0.53) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 | |
| 1,6-Hexanediol SCHEMBL3771601 | 0.97 | CA5A (0.53) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 | |
| 1,6-Hexanediol SCHEMBL9873793 | 0.97 | CA5A (0.53) | CA5ACA5BALDH1A1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943482-B1 | PROCESS FOR THE PREPARATION OF LATANOPROSTENE BUNOD AND INTERMEDIATE THEREOF | CHIROGATE INT INC (TW) | 2025-01-01 | — | — | EP | claimed |
| US-11332433-B2 | Process for the preparation of latanoprostene bunod and intermediate thereof and compositions comprising the same | CHIROGATE INTERNATIONAL INC. (TW) | 2022-05-17 | — | — | US | claimed |
| US-20220024849-A1 | PROCESS FOR THE PREPARATION OF LATANOPROSTENE BUNOD AND INTERMEDIATE THEREOF AND COMPOSITIONS COMPRISING THE SAME | CHIROGATE INTERNATIONAL INC. (TW) | 2022-01-27 | — | — | US | claimed |
| EP-3943482-A1 | PROCESS FOR THE PREPARATION OF LATANOPROSTENE BUNOD AND INTERMEDIATE THEREOF AND COMPOSITIONS COMPRISING THE SAME | Chirogate International Inc. (TW) | 2022-01-26 | — | — | EP | claimed |
| CN-113968807-A | Method for preparing latanoprostene bunodel, intermediate thereof and composition comprising same | 佳和桂科技股份有限公司 | 2022-01-25 | — | — | CN | claimed |
| US-7947855-B2 | Process for the purification of 1,4-butanediol mononitrate | DIPHARMA S.P.A. (IT) | 2011-05-24 | — | — | US | claimed |
| US-20080293961-A1 | PROCESS FOR THE PURIFICATION OF 1,4-BUTANEDIOL MONONITRATE | DIPHARMA S.P.A. (IT) | 2008-11-27 | — | — | US | claimed |
| EP-1560805-B1 | A PROCESS FOR THE PURIFICATION OF 1,4-BUTANEDIOL MONONITRATE | DIPHARMA FRANCIS SRL (IT) | 2007-07-04 | — | — | EP | claimed |
| US-20060135806-A1 | Process for the purification of 1,4-butanediol mononitrate | DIPHARMA S.P.A. (IT) | 2006-06-22 | — | — | US | claimed |
| EP-1560805-A1 | A PROCESS FOR THE PURIFICATION OF 1,4-BUTANEDIOL MONONITRATE | Dipharma S.p.A. (IT) | 2005-08-10 | — | — | EP | claimed |
| WO-2004043897-A1 | A PROCESS FOR THE PURIFICATION OF 1,4-BUTANEDIOL MONONITRATE | DIPHARMA S.P.A. (IT) | 2004-05-27 | — | — | WO | claimed |
| US-12612356-B2 | Process for nitrate ester formation of an α,ω-alkanediol monoacylate | DSM IP ASSETS B.V. (NL) | 2026-04-28 | — | — | US | disclosed |
| US-12522558-B2 | Process for the acylation of an alpha, omega-alkanediol | DSM IP ASSETS B.V. (CH) | 2026-01-13 | — | — | US | disclosed |
| US-20250270178-A1 | METHODS OF PRODUCING A NITRATE ESTER | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-3943482-B1 | PROCESS FOR THE PREPARATION OF LATANOPROSTENE BUNOD AND INTERMEDIATE THEREOF | CHIROGATE INT INC (TW) | 2025-01-01 | — | — | EP | disclosed |
| WO-2004043898-A1 | A PROCESS FOR THE MONONITRATION OF ALKANEDIOLS | DIPHARMA S.P.A. (IT) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043897-A1 | A PROCESS FOR THE PURIFICATION OF 1,4-BUTANEDIOL MONONITRATE | DIPHARMA S.P.A. (IT) | 2004-05-27 | — | — | WO | disclosed |
| US-4536190-A | MIXTURE OF NITRIC ACID ESTERS OF BI(OR TRI-)=CYCLIC ALCOHOLS AND ORGANIC NITRATES | ETHYL CORPORATION (US) | 1985-08-20 | — | — | US | disclosed |
| US-4473378-A | BLEND OF ALKYL NITRATE AND CETANE IMPROVER | ETHYL CORPORATION (US) | 1984-09-25 | — | — | US | disclosed |
| US-3943820-A | Method for charging drill holes with explosive | NITRO NOBEL AB (SW) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612356-B2 | Process for nitrate ester formation of an α,ω-alkanediol monoacylate | ELOVL3, ELOVL1, PTGES | CA5A 2690/4885CA5B 3536/4885ALDH1A1 490/4885 |
| US-20220024849-A1 | PROCESS FOR THE PREPARATION OF LATANOPROSTENE BUNOD AND INTERMEDIATE THEREOF AND COMPOSITIONS COMPRISING THE SAME | PTGIS, PTGES, PTGIR | CA5A 1977/4885CA5B 1916/4885ALDH1A1 871/4885 |
| US-11332433-B2 | Process for the preparation of latanoprostene bunod and intermediate thereof and compositions comprising the same | PTGIS, PTGES, PTGIR | CA5A 1977/4885CA5B 1916/4885ALDH1A1 871/4885 |
| US-20250270178-A1 | METHODS OF PRODUCING A NITRATE ESTER | NOS2, NOS3, NOS1 | CA5A 616/4885CA5B 789/4885ALDH1A1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.